Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
SGSagimet Biosciences Inc. logo

Sagimet Biosciences Inc. (SGMT)

NASDAQ · Currency in USD
$9.58 ▼ -0.37 (-3.72%)
At close: Oct 23, 4:00 PM ET. Market closed.
$9.58 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$9.95
Open
$9.83
Day's Range
$9.49 – $9.91
52 Week Range
$4.50 – $11.45
Volume
694,947
Avg. Volume
1,348,341
Market Cap
$312.13M
Beta (5Y Monthly)
3.49
PE Ratio (TTM)
--
EPS (TTM)
-$0.89
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$20.00

Profile: Sagimet Biosciences Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
16
CEO
David Happel

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.25 · Revenue est. $166.67K
DateEst.Actual
Aug 11, 2026-$0.25-$0.26Miss
May 12, 2026-$0.39-$0.33Beat
Mar 11, 2026-$0.43-$0.29Beat
Nov 13, 2025-$0.41-$0.40Beat
Aug 13, 2025-$0.52-$0.32Beat
May 8, 2025-$0.79-$0.56Beat

Analyst view

Consensus price target
$20.00 ▲ +108.8%
Range $7.00 – $29.00
Rating: Buy
Buy 89% · Hold 11% · Sell 0%

Get free alerts on SGMT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.